Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Date Issued
2024-01-29
Author(s)
Han, Baohui
De La Mora Jiménez, Emmanuel
Lee, Jong-Seok
Koralewski, Piotr
Karadurmus, Nuri
Sugawara, Shunichi
Livi, Lorenzo
Basappa, Naveen S
Quantin, Xavier
Dudnik, Julia
Ortiz, Diego Moran
Mekhail, Tarek
Okpara, Chinyere E
Dutcus, Corina
Zimmer, Zachary
Samkari, Ayman
Bhagwati, Niyati
Csőszi, Tibor
Abstract
Lenvatinib plus pembrolizumab was found to have antitumor activity and acceptable safety in previously treated metastatic NSCLC. We evaluated first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab in metastatic NSCLC in the LEAP-007 study (NCT03829332/NCT04676412).
Subjects
Lenvatinib; Non–small cell lung cancer; Pembrolizumab; Programmed cell death-ligand 1
Type
journal article